NovaBay’s Aganocides Show Penetration And Efficacy In A Pre-Clinical Infected Human Nail Model Of Onychomycosis
NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia. “This model tests both the penetration of the nail as well as the effectiveness of the compounds against the targeted fungus.
Posted by SkinDoc on Saturday, October 31, 2009, at 6:00 am. Filed under Skin Care News. Tagged Amex, Annual Meeting, Antifungal Activity, Compounds, Efficacy, Fungus, Idsa, Infectious Diseases, Infectious Diseases Society, Infectious Diseases Society Of America, Model Tests, Nby, Novabay Pharmaceuticals, Nyse Amex, Penetration, Pharmaceuticals Inc, Philadelphia.
Both comments and trackbacks are currently closed.
